Same Drug Class

Pembrolizumab vs Upadacitinib

Pembrolizumab vs Upadacitinib: Overview

This comparison examines the pharmacological differences between Pembrolizumab and Upadacitinib.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Upadacitinib: Selective JAK1 inhibitor reducing signaling from cytokines implicated in autoimmune diseases.

Pharmacokinetics

Half-life: Pembrolizumab — 26 days; Upadacitinib — 9-14 hours.

Chemical Properties

Molecular Formula: Upadacitinib — C17H19F3N6O.

Molecular Weight: Upadacitinib — 380.3700 g/mol.

Type: Pembrolizumab — Antibody; Upadacitinib — Small molecule.